<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>FOMEPIZOLE - fomepizole injection, solution </strong><br>Sandoz Inc. <br></p></div>
<h1>  Rx only <br>  Sterile <br>  Caution: Must be diluted prior to use. <br>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<br>Fomepizole Injection is a competitive inhibitor of alcohol dehydrogenase. The chemical name of fomepizole is 4-methylpyrazole. It has the molecular formula C<span class="Sub">4</span>H<span class="Sub">6</span>N<span class="Sub">2</span> and a molecular weight of 82.1. The structural formula is:<br><div class="Figure"><img alt="Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a306cd11-9acf-45f1-91ec-9fef2b08fdb1&amp;name=fomepizole-structure.jpg"></div>
<br>It is a clear to yellow liquid at room temperature. Its melting point is 25°C (77°F) and it may present in a solid form at room temperature. Fomepizole is soluble in water and very soluble in ethanol, diethyl ether, and chloroform. Each vial contains 1.5 mL (1 g/mL) of fomepizole.</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<br><span class="Bold">Mechanism of Action</span> : Fomepizole is a competitive inhibitor of alcohol dehydrogenase. Alcohol dehydrogenase catalyzes the oxidation of ethanol to acetaldehyde. Alcohol dehydrogenase also catalyzes the initial steps in the metabolism of ethylene glycol and methanol to their toxic metabolites.<br> <br>Ethylene glycol, the main component of most antifreezes and coolants, is metabolized to glycoaldehyde, which undergoes subsequent sequential oxidations to yield glycolate, glyoxylate, and oxalate. Glycolate and oxalate are the metabolic byproducts primarily responsible for the <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and renal damage seen in ethylene glycol toxicosis. The lethal dose of ethylene glycol in humans is approximately 1.4 mL/kg.<br> <br>Methanol, the main component of windshield wiper fluid, is slowly metabolized via alcohol dehydrogenase to formaldehyde with subsequent oxidation via formaldehyde dehydrogenase to yield formic acid. Formic acid is primarily responsible for the <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (e.g., decreased visual acuity and potential <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>) associated with methanol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>. A lethal dose of methanol in humans is approximately 1 to 2 mL/kg.<br> <br>Fomepizole has been shown in vitro to block alcohol dehydrogenase enzyme activity in dog, monkey, and human liver. The concentration of fomepizole at which alcohol dehydrogenase is inhibited by 50% in vitro is approximately 0.1 µmol/L.<br> <br>In a study of dogs given a lethal dose of ethylene glycol, three animals each were administered fomepizole, ethanol, or left untreated (control group). The three animals in the untreated group became progressively obtunded, moribund, and died. At necropsy, all three dogs had severe renal tubular damage. Fomepizole or ethanol, given 3 hours after ethylene glycol ingestion, attenuated the <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and prevented the renal tubular damage associated with ethylene glycol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.<br> <br>Several studies have demonstrated that fomepizole plasma concentrations of approximately 10 µmol/L (0.82 mg/L) in monkeys are sufficient to inhibit methanol metabolism to formate, which is also mediated by alcohol dehydrogenase. Based on these results, concentrations of fomepizole in humans in the range of 100 to 300 µmol/L (8.6 to 24.6 mg/L) have been targeted to assure adequate plasma concentrations for the effective inhibition of alcohol dehydrogenase.<br> <br>In healthy volunteers, oral doses of fomepizole (10 to 20 mg/kg) significantly reduced the rate of elimination of moderate doses of ethanol, which is also metabolized through the action of alcohol dehydrogenase (see <a href="#Section_6">PRECAUTIONS</a>, <a href="#Section_6.4">Drug Interactions</a>).<br><br><span class="Bold">Pharmacokinetics</span> : The plasma half-life of fomepizole varies with dose, even in patients with normal renal function, and has not been calculated.<br><br><span class="Bold">Distribution</span> : After intravenous infusion, fomepizole rapidly distributes to total body water. The volume of distribution is between 0.6 L/kg and 1.02 L/kg.<br><br><span class="Bold">Metabolism</span> : In healthy volunteers, only 1 to 3.5% of the administered dose of fomepizole (7 to 20 mg/kg oral and IV) was excreted unchanged in the urine, indicating that metabolism is the major route of elimination. In humans, the primary metabolite of fomepizole is 4-carboxypyrazole (approximately 80 to 85% of administered dose), which is excreted in the urine. Other metabolites of fomepizole observed in the urine are 4-hydroxymethylpyrazole and the N-glucuronide conjugates of 4-carboxypyrazole and 4-hydroxymethylpyrazole.<br><br><span class="Bold">Excretion</span> : The elimination of fomepizole is best characterized by Michaelis-Menten kinetics after acute doses, with saturable elimination occurring at therapeutic blood concentrations [100 to 300 µmol/L, 8.2 to 24.6 mg/L].<br> <br>With multiple doses, fomepizole rapidly induces its own metabolism via the cytochrome P450 mixed-function oxidase system, which produces a significant increase in the elimination rate after about 30 to 40 hours. After enzyme induction, elimination follows first-order kinetics.<br><br><span class="Bold">Special Populations</span> :<br><span class="Bold">Geriatric</span> : Fomepizole Injection has not been studied sufficiently to determine whether the pharmacokinetics differ for a geriatric population.<br><br><span class="Bold">Pediatric</span> : Fomepizole has not been studied sufficiently to determine whether the pharmacokinetics differ for a pediatric population.<br><br><span class="Bold">Gender</span> : Fomepizole has not been studied sufficiently to determine whether the pharmacokinetics differ between the genders.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span> : The metabolites of fomepizole are excreted renally. Definitive pharmacokinetic studies have not been done to assess pharmacokinetics in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.<br><br><span class="Bold"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span> : Fomepizole is metabolized through the liver, but no definitive pharmacokinetic studies have been done in subjects with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>.<br><br><span class="Bold">Clinical Studies</span>:<br>The efficacy of fomepizole in the treatment of ethylene glycol and methanol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> was studied in two prospective, U.S. clinical trials without concomitant control groups. Fourteen of 16 patients in the ethylene glycol trial and 7 of 11 patients in the methanol trial underwent hemodialysis because of severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> (see <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>). All patients received fomepizole shortly after admission.<br> <br>The results of these two studies provide evidence that fomepizole blocks ethylene glycol and methanol metabolism mediated by alcohol dehydrogenase in the clinical setting. In both studies, plasma concentrations of toxic metabolites of ethylene glycol and methanol failed to rise in the initial phases of treatment. The relationship to fomepizole therapy, however, was confounded by hemodialysis and significant blood ethanol concentrations in many of the patients. Nevertheless, in the post-dialysis period(s), when ethanol concentrations were insignificant and the concentrations of ethylene glycol or methanol were &gt; 20 mg/dL, the administration of fomepizole alone blocked any rise in glycolate or formate concentrations, respectively.<br> <br>In a separate French trial, 5 patients presented with ethylene glycol concentrations ranging from 46.5 to 345 mg/dL, insignificant ethanol blood concentrations, and normal renal function. These patients were treated with fomepizole alone without hemodialysis, and none developed signs of <span class="product-label-link" type="condition" conceptid="4220631" conceptname="Injury of kidney">renal injury</span>. </div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<br>Fomepizole is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>).</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<br>Fomepizole should not be administered to patients with a documented serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to fomepizole or other pyrazoles.</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-5"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-5.1"></a><p></p>
<h2>General</h2>
<br>Fomepizole should not be given undiluted or by bolus injection. Venous irritation and <span class="product-label-link" type="condition" conceptid="4107595" conceptname="Phlebosclerosis">phlebosclerosis</span> were noted in two of six normal volunteers given bolus injections (over 5 minutes) of fomepizole at a concentration of 25 mg/mL.<br> <br>Minor <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (mild <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>) have been reported in a few patients receiving fomepizole (see <a href="#Section_7">ADVERSE REACTIONS</a>). Therefore, patients should be monitored for signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-5.2"></a><p></p>
<h2>Laboratory Tests</h2>
<br>In addition to specific antidote treatment with fomepizole, patients intoxicated with ethylene glycol or methanol must be managed for <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> (ethylene glycol), <span class="product-label-link" type="condition" conceptid="4195694" conceptname="Adult respiratory distress syndrome">adult respiratory distress syndrome</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> (methanol), and <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>. Fluid therapy and sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> administration are potential supportive therapies. In addition, potassium and calcium supplementation and oxygen administration are usually necessary. Hemodialysis is necessary in the anuric patient, or in patients with severe <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> or <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> (see <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>). Treatment success should be assessed by frequent measurements of blood gases, pH, electrolytes, BUN, creatinine, and urinalysis, in addition to other laboratory tests as indicated by individual patient conditions. At frequent intervals throughout the treatment, patients poisoned with ethylene glycol should be monitored for ethylene glycol concentrations in serum and urine, and the presence of urinary oxalate crystals. Similarly, serum methanol concentrations should be monitored in patients poisoned with methanol.<br><br>Electrocardiography should be performed because <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span> can affect the cardiovascular system. In the <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">comatose</span> patient, electroencephalography may also be required. In addition, hepatic enzymes and white blood cell counts should be monitored during treatment, as transient increases in serum transaminase concentrations and <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> have been noted with repeated fomepizole dosing.  </div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-5.3"></a><p></p>
<h2>Drug Interactions</h2>
<br>Oral doses of fomepizole (10 to 20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses. Similarly, ethanol decreased the rate of elimination of fomepizole (by approximately 50%) by the same mechanism.<br><br>Reciprocal interactions may occur with concomitant use of fomepizole and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied.</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-5.4"></a><p></p>
<h2>Carcinogenesis &amp; Mutagenesis &amp; Impairment Of Fertility</h2>
<br>There have been no long-term studies performed in animals to evaluate carcinogenic potential.<br> <br>There was a positive Ames test result in the Escherichia coli tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> WP2uvrA and the <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA102 in the absence of metabolic activation. There was no evidence of a clastogenic effect in the in vivo mouse micronucleus assay.<br> <br>In rats, fomepizole (110 mg/kg) administered orally for 40 to 42 days resulted in decreased testicular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> (approximately 8% reduction). This dose is approximately 0.6 times the human maximum daily exposure based on surface area (mg/m2). This reduction was similar for rats treated with either ethanol or fomepizole alone. When fomepizole was given in combination with ethanol, the decrease in testicular <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> was significantly greater (approximately 30% reduction) compared to those rats treated exclusively with fomepizole or ethanol.</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-5.5"></a><p></p>
<h2>Pregnancy</h2>
<br><p class="First">Pregnancy Category C : Animal reproduction studies have not been conducted with fomepizole. It is also not known whether fomepizole can cause fetal harm when administered to pregnant women or can affect reproduction capacity. Fomepizole should be given to pregnant women only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-5.6"></a><p></p>
<h2>Nursing Mothers</h2>
<br>It is not known whether fomepizole is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when fomepizole is administered to a nursing woman.</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-5.7"></a><p></p>
<h2>Pediatric Use</h2>
<br>Safety and effectiveness in pediatric patients have not been established.</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_6.11"></a><a name="section-5.8"></a><p></p>
<h2>Geriatric Use</h2>
<br>Safety and effectiveness in geriatric patients have not been established.</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<br>The most frequent adverse events reported as drug-related or unknown relationship to study drug in the 78 patients and 63 normal volunteers who received fomepizole injection were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (14%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (11%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, increased <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, and bad taste/metallic taste (6% each). All other adverse events in this population were reported in approximately 3% or fewer of those receiving fomepizole and were as follows:<br><br><span class="Bold">Body as a Whole</span> : <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, multiorgan system failure, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> during fomepizole injection, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> at injection site, lumbalgia/<span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="4137607" conceptname="Hangover">hangover</span>.<br><br><span class="Bold">Cardiovascular</span> : <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">Sinus bradycardia</span>/<span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="4107595" conceptname="Phlebosclerosis">phlebosclerosis</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.<br><br><span class="Bold">Gastrointestinal</span> : <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">heartburn</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, transient transaminitis.<br><br><span class="Bold">Hemic/Lymphatic</span> : <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span>/<span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">hypereosinophilia</span>, <span class="product-label-link" type="condition" conceptid="439840" conceptname="Lymphangitis">lymphangitis</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>.<br><br><span class="Bold">Nervous</span> : <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4012565" conceptname="Feeling intoxicated">feeling drunk</span>, facial flush, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">nystagmus</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, "felt strange", decreased environmental awareness.<br><br><span class="Bold">Respiratory </span>: <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccups</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.<br><br><span class="Bold">Skin/Appendages</span> : <span class="product-label-link" type="condition" conceptid="4319310" conceptname="Application site reaction">Application site reaction</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.<br><br><span class="Bold">Special Senses</span> : Abnormal smell, speech/<span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, transient <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, roar in ear. <br><br><span class="Bold">Urogenital</span> : <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">Anuria</span></div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-7"></a><p></p>
<h1>OVERDOSAGE</h1>
<br><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, and <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> were noted in healthy volunteers receiving 50 and 100 mg/kg doses of fomepizole (at plasma concentrations of 290 to 520 µmol/L, 23.8 to 42.6 mg/L). These doses are 3 to 6 times the recommended dose. This dose-dependent CNS effect was short-lived in most subjects and lasted up to 30 hours in one subject.<br><br>Fomepizole is dialyzable, and hemodialysis may be useful in treating cases of overdosage.</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-8"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<br><span class="Bold">Treatment Guidelines</span> : If ethylene glycol or methanol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> is left untreated, the natural progression of the <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> leads to accumulation of toxic metabolites, including glycolic and oxalic acids (ethylene glycol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>) and formic acid (methanol <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>). These metabolites can induce <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, calcium oxaluria, <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">acute tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">blindness</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The diagnosis of these <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisonings</span> may be difficult because ethylene glycol and methanol concentrations diminish in the blood as they are metabolized to their respective metabolites. Hence, both ethylene glycol and methanol concentrations and acid base balance, as determined by serum electrolyte (<span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>) and/or arterial blood gas analysis, should be frequently monitored and used to guide treatment.<br><br>Treatment consists of blocking the formation of toxic metabolites using inhibitors of alcohol dehydrogenase, such as fomepizole, and correction of metabolic abnormalities. In patients with high ethylene glycol or methanol concentrations (≥ 50 mg/dL), significant <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, hemodialysis should be considered to remove ethylene glycol or methanol and the respective toxic metabolites of these alcohols.<br><br><span class="Bold">Treatment with fomepizole</span> :Begin fomepizole treatment immediately upon suspicion of ethylene glycol or methanol ingestion based on patient history and/or <span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span> <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, increased osmolar gap, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, or oxalate crystals in the urine, OR a documented serum ethylene glycol or methanol concentration greater than 20 mg/dL.<br><br><span class="Bold">Hemodialysis</span> :Hemodialysis should be considered in addition to fomepizole in the case of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, significant or worsening <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, or a measured ethylene glycol or methanol concentration of greater than or equal to 50 mg/dL. Patients should be dialyzed to correct metabolic abnormalities and to lower the ethylene glycol concentrations below 50 mg/dL.<br><br><span class="Bold">Discontinuation of fomepizole Treatment</span> :Treatment with fomepizole may be discontinued when ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH.<br><br><span class="Bold">Dosing of fomepizole</span> :A loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 hours for 4 doses, then 15 mg/kg every 12 hours thereafter until ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL, and the patient is asymptomatic with normal pH. All doses should be administered as a slow intravenous infusion over 30 minutes (see Administration).<br><br><span class="Bold">Dosage with Renal Dialysis</span> : Fomepizole Injection is dialyzable and the frequency of dosing should be increased to every 4 hours during hemodialysis.<br><br> <br><span class="Bold">Fomepizole Dosing in Patients Requiring Hemodialysis</span><br> <br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">DOSE AT THE BEGINNING OF HEMODIALYSIS</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"> <span class="Bold">If &lt;6 hours since last fomepizole dose</span>
</td>
<td class="Rrule" valign="top"><span class="Bold"> If ≥ 6 hours since last fomepizole dose</span></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"> Do not administer dose</td>
<td class="Rrule" valign="top"> Administer next scheduled dose</td>
</tr>
</tbody></table>
<br> <br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" valign="top"> <span class="Bold">DOSING DURING HEMODIALYSIS</span>
</td></tr>
<tr class="Last"><td class="Lrule Rrule" valign="top"> Dose every 4 hours</td></tr>
</tbody></table>
<br> <br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" colspan="2" valign="top"><span class="Bold">DOSING AT THE TIME HEMODIALYSIS IS COMPLETED</span></td></tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="Bold">Time between last dose and the end of<br>hemodialysis</span></td>
<td class="Rrule" valign="top"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="Bold">&lt;1 hour</span></td>
<td class="Rrule" valign="top">Do not administer dose at the end of<br>hemodialysis</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top"><span class="Bold">1-3 hours</span></td>
<td class="Rrule" valign="top">Administer 1/2 of next scheduled dose</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top"><span class="Bold">&gt;3 hours</span></td>
<td class="Rrule" valign="top">Administer next scheduled dose</td>
</tr>
</tbody></table>
<br><br><br><br><table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody class="Headless">
<tr class="Botrule First"><td class="Lrule Rrule" valign="top"><span class="Bold">MAINTENANCE DOSING OFF HEMODIALYSIS</span></td></tr>
<tr class="Last"><td class="Lrule Rrule" valign="top"> Give next scheduled dose 12 hours from last dose administered</td></tr>
</tbody></table>
<br><br><span class="Bold">Administration</span> : Fomepizole solidifies at temperatures less than 25°C (77°F). If the fomepizole solution has become solid in the vial, the solution should be liquefied by running the vial under warm water or by holding in the hand. Solidification does not affect the efficacy, safety, or stability of fomepizole. Using sterile technique, the appropriate dose of fomepizole should be drawn from the vial with a syringe and injected into at least 100 mL of sterile 0.9% sodium chloride injection or dextrose 5% injection. Mix well. The entire contents of the resulting solution should be infused over 30 minutes. Fomepizole, like all parenteral products, should be inspected visually for particulate matter prior to administration.<p class="First"><span class="Bold">Stability</span> : Fomepizole diluted in 0.9% sodium chloride injection or dextrose 5% injection remains stable and sterile for at least 24 hours when stored refrigerated or at room temperature. Fomepizole does not contain preservatives. Therefore, maintain sterile conditions, and after dilution do not use beyond 24 hours.</p>
<p>Solutions showing haziness, particulate matter, precipitate, discoloration, or leakage should not be used.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<br>Fomepizole Injection is available as a sterile, preservative-free solution for intravenous use, in vials containing 1.5mL (1 g/mL) of fomepizole. <br>Fomepizole injection is supplied in cartons of one single use vial (NDC 0781-3182-73). or four individual cartons placed into one outer carton (NDC 0781-3182-84).<br> <br>Store at controlled room temperature, 20° to 25°C (68° to 77°F).<br><br><span class="Bold">Manufactured By</span>:<br><span class="Bold">Emcure Pharmaceuticals Ltd.</span><br>Pune 411 057, INDIA for:<br>Sandoz Inc.<br>Princeton, NJ 08540</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-10"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<br>FOMEPIZOLE INJECTION<br>1.5g/1.5mL (1g/mL)<br>Rx Only<br>Single use vial<br>NDC 0781-3182-73<br>For intravenous infusion only<br>Caution: Must be diluted before use.<br>Store at controlled room temperature, 20°-25°C (68°-77°F) [see USP].<br>Manufactured by: Emcure Pharmaceuticals Ltd.<br>for: Sandoz Inc., Princeton, NJ 08540<br><div class="Figure"><img alt="Principlal display panel-label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a306cd11-9acf-45f1-91ec-9fef2b08fdb1&amp;name=Fomepizole-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Unclassified_Section_2"></a><a name="section-11"></a><p></p>
<h1>PACKAGE CARTON PRINCIPAL DISPLAY PANEL</h1>
<br><br>FOMEPIZOLE INJECTION<br>1.5g/1.5mL (1g/mL)<br>Rx Only<br>One single use vial<br>NDC 0781-3182-73<br>For intravenous infusion only<br>Caution: Must be diluted before use.<br>Contains: One 1.5mL (1g/mL) vial of Fomepizole Injection.<br>Each mL contains: 1g Fomepizole<br>Dosage and Administration: See package insert for dosage and administration information.<br>Store at controlled room temperature, 20°-25°C (68°-77°F) [see USP].<br>KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.<br>Manufactured by: Emcure Pharmaceuticals Ltd.<br>for: Sandoz Inc., Princeton, NJ 08540<br><div class="Figure"><img alt="Principal display panel-inner carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a306cd11-9acf-45f1-91ec-9fef2b08fdb1&amp;name=Fomepizole-2.jpg"></div>
<br> <br> </div>
<div class="Section" data-sectionCode="51945-4">
<a name="Unclassified_Section_3"></a><a name="section-12"></a><p></p>
<h1>PACKAGE OUTER CARTON PRINCIPAL DISPLAY PANEL</h1>
<br><br><br>FOMEPIZOLE INJECTION<br>1.5g/1.5mL (1g/mL)<br>Rx Only<br>Four single use vials<br>NDC 0781-3182-84<br>For intravenous infusion only<br>Caution: Must be diluted before use.<br>Contains: Four1.5mL (1g/mL) vials of Fomepizole Injection.<br>Each mL contains: 1g Fomepizole<br>Dosage and Administration: See package insert for dosage and administration information.<br>Store at controlled room temperature, 20°-25°C (68°-77°F) [see USP].<br>KEEP THIS AND ALL DRUGS OUT OF THE REACH OF CHILDREN.<br><br>Manufactured by: Emcure Pharmaceuticals Ltd.<br>for: Sandoz Inc., Princeton, NJ 08540<br><div class="Figure"><img alt="Principal display panel-outer carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a306cd11-9acf-45f1-91ec-9fef2b08fdb1&amp;name=Fomepizole-1.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>FOMEPIZOLE 		
					</strong><br><span class="contentTableReg">fomepizole injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0781-3182</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>FOMEPIZOLE</strong> (FOMEPIZOLE) </td>
<td class="formItem">FOMEPIZOLE</td>
<td class="formItem">1 g  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-3182-84</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0781-3182-73</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1.5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA078537</td>
<td class="formItem">03/06/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sandoz Inc. 
							(110342024)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Emcure Pharmaceuticals Ltd.</td>
<td class="formItem"></td>
<td class="formItem">916921919</td>
<td class="formItem">MANUFACTURE, ANALYSIS</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a306cd11-9acf-45f1-91ec-9fef2b08fdb1</div>
<div>Set id: a306cd11-9acf-45f1-91ec-9fef2b08fdb1</div>
<div>Version: 1</div>
<div>Effective Time: 20100628</div>
</div>
</div> <div class="DistributorName">Sandoz Inc. </div></p>
</body></html>
